- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06688084
Pathogenitätsfaktoren von Staphylococcus Pettenkoferi bei Fußwunden und Osteitis bei Diabetikern (PETTENK-OS)
Bewertung der Pathogenitätsfaktoren von Staphylococcus Pettenkoferi bei Fußwunden und Osteitis bei Diabetikern. Die PETTENK-OS-Studie
Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Sonstiges: Molecular epidemiology of the collection
- Sonstiges: Study of the resistome of the S. pettenkoferi population
- Sonstiges: Study of the virulome of the S. pettenkoferi population
- Sonstiges: Study of the resistance profiles of all S. pettenkoferi isolates
- Sonstiges: Selection of strains for in-depth phenotypic study
- Sonstiges: Selection of strains (n=3) for the virulence study
Detaillierte Beschreibung
Gram-positive cocci, in particular Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. While studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no study has focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is not known. Yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. In the work of Loetsche et al. a study of the microbiome of 349 diabetic foot ulcer samples by targeted 16S rDNA sequencing showed that the genus Staphylococcus was the most abundant, with a relative abundance of 22.8%, including 13.3% S. aureus and 5.3% S. pettenkoferi.
At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory (89 isolations of S. pettenkoferi from diabetic foot ulcer samples out of 167 isolations made of this bacterium between 2018 and 2022).The difficulty of managing chronic wounds also lies in the fact that almost 80% of the bacteria present are in biofilms. It has also been established that the environment in which bacteria are found, and in particular the interactions they establish between themselves, play a significant role in delayed wound healing. It is therefore essential to understand the mechanisms governing these bacterial interactions and to establish the true pathogenic potential of these bacteria.
Recently, our team demonstrated that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. As well as being able to produce biofilm, SP165 was able to survive in human blood, human keratinocytes and murine and human macrophages. It also demonstrated its virulence by causing significant embryonic mortality in the zebrafish model.
A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated the existence of two predominant clones with different virulences.
Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish virulence profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Gard
-
Nîmes, Gard, Frankreich, 30029
- Nîmes University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The collection of strains at the Nîmes University Hospital site from 9 European laboratories collected between 2015 and 2023 for a total of 108 months was carried out between November 2021 and August 2023.
Beschreibung
Inclusion Criteria:
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Exclusion Criteria:
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: OTHER
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Zeitfenster: Day 0 to 3 months
|
Number of clades estimated via typing by complete sequencing of the bacterial genomes of all S. pettenkoferi strains and analysis of phylogenetic distances (whole genome and core genome single nucleotide polymorphisms). |
Day 0 to 3 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Zeitfenster: 3 - 6 months
|
Number of clades estimated via typing by complete sequencing of the bacterial genomes of all Staphylococcus pettenkoferi strains and analysis of phylogenetic distances. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin:osteitis
Zeitfenster: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: non-diabetic wounds
Zeitfenster: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: diabetic wounds
Zeitfenster: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: blood cultures
Zeitfenster: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: nasal carriage
Zeitfenster: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: osteitis
Zeitfenster: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: non-diabetic wounds
Zeitfenster: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: diabetic wounds
Zeitfenster: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: blood cultures
Zeitfenster: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: nasal carriage
Zeitfenster: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: osteitis
Zeitfenster: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: non-diabetic wounds
Zeitfenster: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: diabetic wounds
Zeitfenster: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: blood cultures
Zeitfenster: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: nasal carriage
Zeitfenster: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Phenotypic resistance profiles in the population in a subsample of 85 strains
Zeitfenster: 6 - 14 months
|
The minimum inhibitory concentration for a series of antibiotics will be recorded (antibiograms of isolates).These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: osteitis
Zeitfenster: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: non-diabetic wounds
Zeitfenster: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: diabetic wounds
Zeitfenster: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: blood cultures
Zeitfenster: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: nasal carriage
Zeitfenster: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: osteitis
Zeitfenster: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: non-diabetic wounds
Zeitfenster: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: diabetic wounds
Zeitfenster: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: blood cultures
Zeitfenster: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: nasal carriage
Zeitfenster: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: osteitis
Zeitfenster: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: non-diabetic wounds
Zeitfenster: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: diabetic wounds
Zeitfenster: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: blood cultures
Zeitfenster: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: nasal carriage
Zeitfenster: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: osteitis
Zeitfenster: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from osteitis
Zeitfenster: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: diabetic wounds
Zeitfenster: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from diabetic wounds
Zeitfenster: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: blood cultures
Zeitfenster: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from blood cultures
Zeitfenster: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: nasal carriage
Zeitfenster: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from nasal carriage
Zeitfenster: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from osteitis
Zeitfenster: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from non-diabetic wounds
Zeitfenster: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from diabetic wounds
Zeitfenster: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from blood cultures
Zeitfenster: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from nasal carriage
Zeitfenster: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Chloé MAGNAN, Dr., Nîmes University Hospital, FRANCE
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Magnan C, Curtil-Dit-Galin M, Morsli M, Cattoir V, Piau-Couapel C, Soderquist B, Kahl BC, Denis O, Rwayane K, Corvec S, Francois P, Salipante F, Pantel A, Dunyach-Remy C, Laurent F, Lavigne JP; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS). Staphylococcus pettenkoferi: an underrecognized species with clinically relevant antimicrobial resistance. A comprehensive genomic European study. Emerg Microbes Infect. 2026 Dec;15(1):2724635. doi: 10.1080/22221751.2026.2724635. Epub 2026 Sep 16.
- Magnan C, Plumet L, Morsli M, Dunyach-Remy C, Pouget C, Sotto A, Molle V, Lavigne J-P. A narrative review of coagulase-negative staphylococci in diabetic foot infections. Clin Microbiol Rev. 2025 Dec 11;38(4):e0012125. doi: 10.1128/cmr.00121-25. Epub 2025 Nov 4.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Knochenerkrankungen
- Erkrankungen des Bewegungsapparates
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Stoffwechselerkrankungen
- Störungen des Glukosestoffwechsels
- Diabetische Angiopathien
- Diabetes-Komplikationen
- Hautkrankheiten
- Hautgeschwür
- Beingeschwür
- Diabetische Neuropathien
- Fußgeschwür
- Ernährungs- und Stoffwechselerkrankungen
- Haut- und Bindegewebserkrankungen
- Diabetes Mellitus
- Infektionen
- Diabetischer Fuß
- Ostitis
Andere Studien-ID-Nummern
- NIMAO/2023-2/CM-01
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .